NCT03414333View on ClinicalTrials.gov

To Determine the Effect of GLP1 on Cognitive Function, Brain Glucose Metabolism and Neuroplasticity.

NACompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

June 29, 2016

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2018

Conditions
Glucose Metabolism DisordersObesityDegenerative Brain Disorder
Interventions
PROCEDURE

RYGB

RYGB is associated with a increase of circulating GLP-1 (up to ten-fold) especially in response to meal ingestion. This increased availability of GLP1 has been claimed to contribute to restoration of some of the beta-cell function.

DRUG

GLP-1

GLP-1 is an hormone secreted by gut in response to nutrients ingestion.

Trial Locations (1)

Unknown

Dept.Clinical and Experimental Medicine.Section of Diabetes., Pisa

All Listed Sponsors
lead

University of Pisa

OTHER

NCT03414333 - To Determine the Effect of GLP1 on Cognitive Function, Brain Glucose Metabolism and Neuroplasticity. | Biotech Hunter | Biotech Hunter